HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

glycine amide

RN given refers to parent cpd
Also Known As:
glycinamide; glycine amide hydrobromide; glycine amide hydrochloride; 2-aminoacetamide
Networked: 34 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Mishra, Ram K: 3 articles (01/2011 - 12/2005)
2. Basurto, Enrique: 2 articles (08/2015 - 09/2014)
3. Castellano, Jessica M: 2 articles (10/2007 - 12/2005)
4. Mann, Amandeep: 2 articles (10/2007 - 12/2005)
5. Verma, Vaneeta: 2 articles (10/2007 - 12/2005)
6. Johnson, Rodney L: 2 articles (10/2007 - 12/2005)
7. Pietra, C: 2 articles (09/2001 - 06/2001)
8. Villetti, G: 2 articles (09/2001 - 06/2001)
9. Flores, Oscar González: 1 article (08/2015)
10. Hoffman, Kurt Leroy: 1 article (08/2015)

Related Diseases

1. Parkinson Disease (Parkinson's Disease)
2. Neuroblastoma
3. Epilepsy (Aura)
4. Drug-Induced Dyskinesia (Dyskinesia, Drug Induced)
5. Movement Disorders (Movement Disorder)
12/11/1981 - "An animal model of tardive dyskinesia was used to evaluate the potential antidyskinetic properties of the neuropeptide L-prolyl-L-leucyl-glycinamide (PLG). "
02/01/2003 - "In the present experimental paradigm, we examine the effect of L-prolyl-L-leucyl-glycinamide (PLG) co-administration with haloperidol on vacuous chewing movements (VCM) in rats-a model of tardive dyskinesia (TD) in humans. "
02/01/2003 - "Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia."
10/01/2007 - "Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino]-3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. "
05/01/1985 - "An animal model of tardive dyskinesia was used for the evaluation of potential antidyskinetic properties of the neuropeptide L-Prolyl-L-Leucyl-glycinamide (PLG) and related drugs: cyclo[glycine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Gly) and cyclo[alanine-(1-amino-1-cyclopentane) carbonyl]--c(CPC-Ala). "

Related Drugs and Biologics

1. Neuropeptides
2. 3- (N- prolylamine)- 2- oxo- 1- pyrrolidineacetamide
3. Levodopa (L Dopa)
4. Dopamine (Intropin)
5. DP-VPA
6. isovaleramide
7. Glycine (Aminoacetic Acid)
8. Hypoxanthine
9. Hormones
10. Haloperidol (Haldol)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Oral Administration